Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Marrone Bio Innovations, Inc. MBII
$0.80
На 13:46, 16 марта 2023
Ранг: 3
Ключевые показатели
-
Marketcap
0.00000000
-
week52high
1.50
-
week52low
0.55
-
Revenue
44310000
-
P/E TTM
-11
-
Beta
0.35504400
-
EPS
-0.11700000
-
Last Dividend
0.00000000
-
Next Earnings Date
15 авг 2022 г. в 04:00
Описание компании
Marrone Bio Innovations, Inc. discovers, develops, and sells biological products for crop protection, crop health, and crop nutrition. Its products include Emergen, Foramin, Foramin ST, Optima, Takla, Pacesetter, Ympact, UBP, and UBP ST for increasing crop health, yield, and quality; Grandevo, a bioinsecticide that controls sucking and chewing insects through feeding; Haven, a plant health product to reduce sun stress and dehydration; Jet-Ag and Jet-Oxide peroxyacetic acid sanitizers that prevent, suppress, eliminate, and control algae, fungi, and bacterial diseases in agriculture and horticultural industries; and Majestene, a bionematicide to control soil-dwelling nematodes and certain soil borne insects. The company also offers Regalia and Stargus, which protects against fungal and bacterial diseases and enhances yields/quality; Venerate, a bioinsecticide that controls chewing and sucking insects and mites; and Zelto, a bionematicide that protects turf, including golf course fairways and greens, and promotes turf health by enhancing plant and root health. It provides its products directly through sales force, as well as through distributors and other commercial partners. The company formerly known as Marrone Organic Innovations, Inc. Marrone Bio Innovations, Inc. was incorporated in 2006 and is headquartered in Raleigh, North Carolina.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Roth Capital | Buy | 22 сент 2021 г. | |
| Aegis Capital | Buy | Buy | 19 авг 2021 г. |
| Aegis Capital | Buy | Buy | 11 февр 2021 г. |
| Aegis Capital | Buy | Buy | 14 авг 2020 г. |
| Canaccord Genuity | Buy | 28 июл 2020 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Vasavada Amit | D | 0 | 40000 | 12 июл 2022 г. |
| Vasavada Amit | D | 0 | 40000 | 12 июл 2022 г. |
| Vasavada Amit | D | 0 | 129184 | 12 июл 2022 г. |
| Vasavada Amit | D | 0 | 40000 | 12 июл 2022 г. |
| Vasavada Amit | A | 285892 | 129184 | 12 июл 2022 г. |
| Johnson Timothy B | D | 0 | 33333 | 12 июл 2022 г. |
| Johnson Timothy B | D | 0 | 102167 | 12 июл 2022 г. |
| Johnson Timothy B | D | 0 | 33333 | 12 июл 2022 г. |
| Johnson Timothy B | A | 212374 | 102167 | 12 июл 2022 г. |
| Ospraie Ag Science LLC | D | 0 | 70836258 | 12 июл 2022 г. |
Новостная лента
Marrone Bio's (MBII) Earnings and Revenues Miss Estimates in Q1
Zacks Investment Research
17 мая 2022 г. в 14:18
Marrone Bio (MBII) witnessed increased sales of row crop products in the first quarter, offset by lower sales into specialty crop markets.
Marrone Bio Innovations, Inc. (MBII) CEO Kevin Helash on Q1 2022 Results - Earnings Call Transcript
Seeking Alpha
11 мая 2022 г. в 20:01
Marrone Bio Innovations, Inc. (NASDAQ:MBII ) Q1 2022 Earnings Conference Call May 11, 2022 4:30 PM ET Company Participants Kevin Helash – Chief Executive Officer Linda Moore – Chief Legal Officer LaDon Johnson – Interim Chief Financial Officer Matti Tiainen – Senior Vice President International Sales Kamal El Mernissi – Senior Director of Product & Marketing Conference Call Participants Dmitry Silversteyn – Water Tower Research Operator Good afternoon ladies and gentlemen, and welcome to the First Quarter 2022 Earnings conference call. At this time all participants are in a listen-only mode.
Marrone Bio Innovations, Inc. (MBII) Reports Q1 Loss, Lags Revenue Estimates
Zacks Investment Research
11 мая 2022 г. в 18:49
Marrone Bio Innovations, Inc. (MBII) delivered earnings and revenue surprises of -300% and 8.29%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Marrone Bio Innovations, Inc. (MBII) Reports Q4 Loss, Tops Revenue Estimates
Zacks Investment Research
28 мар 2022 г. в 21:49
Marrone Bio Innovations, Inc. (MBII) delivered earnings and revenue surprises of 0% and 3.85%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Marrone Bio Innovations, Inc. (MBII) CEO Kevin Helash on Q4 2021 Results - Earnings Call Transcript
Seeking Alpha
28 мар 2022 г. в 19:48
Marrone Bio Innovations, Inc. (MBII) CEO Kevin Helash on Q4 2021 Results - Earnings Call Transcript